Glenmark Pharmaceuticals has announced the launch of its Airz-FF glycopyrronium/formoterol/fluticasone propionate triple combination inhaler for the treatment of COPD in India. The company said that “AIRZ-FF has been exclusively studied in the Indian population and introduced to address challenges faced by a significant portion of COPD patients in the country.”
Glenmark President, India Formulations, Middle East and Africa, Sujesh Vasudevan said, “COPD poses a significant public health challenge in India for many reasons. When it comes to treatment, there is poor patient compliance and adherence to prescribed doses, owing to the need for multiple inhalers through the day. By introducing AIRZ-FF, we hope to reduce this burden for patients, by delivering three effective therapies together in the same inhaler. Glenmark continues to invent and innovate healthcare solutions that meet specific and often hard-to-address needs of patients in India and the world.”
Read the Glenmark Pharmaceuticals press release.
